Bioceros Holding

Bioceros is a Netherlands-based biotechnology company specializing in the development of high-yield mammalian cell lines for the production of therapeutic proteins, including monoclonal antibodies and biosimilars. The company is best known for its proprietary CHOBC platform, a Chinese Hamster Ovary cell line system designed to achieve high titers and stable production for complex biologics. In 2016, Bioceros was acquired by Polpharma Biologics, where it now serves as a center of excellence for cell line development and early-stage process development. The company provides a comprehensive suite of services ranging from molecular biology and cell line engineering to the generation of research cell banks. Their expertise supports the development of both innovative biologics and biosimilars, facilitating the transition from discovery to large-scale GMP manufacturing. As part of the Polpharma Biologics group, Bioceros plays a critical role in the vertical integration of the parent company's global biologics pipeline.